|
Intravitreal Tissue Plasminogen Activator in Diabetic Vitreous Hemorrhage
|
|
| Author:
|
NIYOUSHA MOHAMMAD REZA, AHOOR MOHAMMAD HOSEIN, HASHEMI HESAMSADAT, EFTEKHARI MILANI AMIR , HASANPOOR NARGES, NAJAFI AMIN
|
| Abstract:
|
Background and Purpose: Vitreous hemorrhage is one of the most common complications of
diabetic retinopathy that causes significant visual impairment. So, the aim of this research was
evaluation of the effect of intravitreal tissue plasminogen activator (tPA) on diabetic vitreous
hemorrhage.
Material and Methods: This is a Double blinded randomized clinical trial on 15 patients with diabetic
vitreous hemorrhage received single dose of 80µ in 0.1 ml tPA intravitrealy and 15 patients received
1.25 mg intravitreal Bevacizumab (IVB). Visual acuity and vitreous hemorrhage grading before and
after intervention were evaluated as main outcome.
Results: 30 patients completed our study (15 patients in each group). Primary characteristics of two
group had no differences significantly. Visual acuity before intervention had no significant difference
between groups. After intervention visual acuity was significantly better in IVB group compared to tPA
group (P=0.027). There was no significant difference between groups in term of vitreous hemorrhage
grading before and after intervention. Visual acuity and grading of vitreous hemorrhage improved
after intervention compared to the baseline in both groups.
Conclusion: TPA is statistically effective in resolution of diabetic vitreous hemorrhage however, its
effect is less than bevacizumab and its clinical benefit comparing to observation may need more
evaluation.
|
| Keyword:
|
Intravitreal Tissue Plasminogen Activator, Diabetic Vitreous Hemorrhage.
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|